Q-omics provides the consensus-scored NLRP2B profile across patient tissues and cancer cell-line models. NLRP2B expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, NLRP2B is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, NLRP2B RNA expression shows 10,895 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRP, KIRC, and THYM as cancer lineages where NLRP2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NLRP2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NLRP2B survival associations across molecular data types. NLRP2B RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NLRP2B RNA expression–survival associations across cancer types. High NLRP2B expression shows unfavorable associations in LAML, LUAD, OV, MESO and THCA, but favorable associations in KIRP. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .010). Together, the overview and detailed table identify KIRP as the clearest survival context for NLRP2B RNA expression.
This table summarizes NLRP2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NLRP2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NLRP2B shows lower tumor expression in LUAD, THCA, UCEC and KICH and higher tumor expression in KIRC and LIHC. The KIRC box plot shows higher NLRP2B RNA expression in tumor versus normal tissue (log2 FC = +0.057, t-test p < 0.001).
This table shows molecular features associated with NLRP2B in patient tissues and cancer cell lines. In patient samples, NLRP2B shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, NLRP2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia.
